NT-proBNP correlates with LVEF decline in HER2-positive breast cancer patients treated with trastuzumab.

Autor: Bouwer NI; 1Department of Internal Medicine, Albert Schweitzer Hospital, 3300 AK, Dordrecht, South-Holland The Netherlands.; 2Department of Cardiology, Albert Schweitzer Hospital, 3300 AK, Dordrecht, South-Holland The Netherlands., Liesting C; 2Department of Cardiology, Albert Schweitzer Hospital, 3300 AK, Dordrecht, South-Holland The Netherlands., Kofflard MJM; 2Department of Cardiology, Albert Schweitzer Hospital, 3300 AK, Dordrecht, South-Holland The Netherlands., Sprangers-van Campen SM; 1Department of Internal Medicine, Albert Schweitzer Hospital, 3300 AK, Dordrecht, South-Holland The Netherlands., Brugts JJ; 3Department of Cardiology, Erasmus MC, University Medical Center Rotterdam, 3000 CA, Rotterdam, South-Holland The Netherlands., Kitzen JJEM; 1Department of Internal Medicine, Albert Schweitzer Hospital, 3300 AK, Dordrecht, South-Holland The Netherlands., Fouraux MA; 4Result Laboratorium C.V, Albert Schweitzer Hospital, 3300 AK, Dordrecht, South-Holland The Netherlands., Levin MD; 1Department of Internal Medicine, Albert Schweitzer Hospital, 3300 AK, Dordrecht, South-Holland The Netherlands., Boersma E; 3Department of Cardiology, Erasmus MC, University Medical Center Rotterdam, 3000 CA, Rotterdam, South-Holland The Netherlands.

Publikováno v: Cardio-oncology (London, England) [Cardiooncology] 2019 May 28; Vol. 5, pp. 4. Date of Electronic Publication: 2019 May 28 (Print Publication: 2019).